View Older Stories View More Recent Stories
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Johnson & Johnson (JNJ) seeks U.S. FDA approval for first pediatric indications for TREMFYA
-
Johnson & Johnson (JNJ) seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
-
Johnson & Johnson (JNJ) reports icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
-
Johnson & Johnson (JNJ) call put ratio 1 call to 1.9 puts
-
Johnson & Johnson (JNJ) reports nipocalimab demonstrated significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
-
Johnson & Johnson (JNJ): Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren
-
Johnson & Johnson (JNJ) submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
-
Johnson & Johnson (JNJ): TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
-
Starboard Value Builds Stake In Tylenol-Maker Kenvue - WSJ
-
Johnson & Johnson (JNJ) PT Raised to $181 at RBC Capital
-
Johnson & Johnson (JNJ) PT Raised to $170 at Stifel
-
Citi Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 23c, Beats on Revenue
-
Johnson & Johnson reports earnings ahead of the open. Here's what to know
-
Johnson & Johnson (JNJ) October option implied volatility into quarter results
-
Johnson & Johnson (JNJ) October 160 straddle priced into quarter results
-
Johnson & Johnson (JNJ) October 160 straddle priced into quarter results
-
Johnson & Johnson's (JNJ) TREMFYA demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
-
Stifel Reiterates Hold Rating on Johnson & Johnson (JNJ) on V-Wave acquisition
-
Wells Fargo Reiterates Equal Weight Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) Completes Acquisition of V-Wave
-
Johnson & Johnson (JNJ) reports ERLEADA demonstrated statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration
-
Johnson & Johnson (JNJ) files for U.S. FDA approval of DARZALEX FASPRO-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
-
Johnson & Johnson (JNJ) Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
-
Johnson & Johnson (JNJ) reports CARVYKTI is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second lin
-
Johnson & Johnson (JNJ) reports DARZALEX-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
-
Johnson & Johnson's (JNJ) DARZALEX FASPRO-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not p
-
J&J (JNJ): Novel combination of TALVEY and TECVAYLI suggests high response rates and durable responses in triple-class refractory patients with r/r multiple myeloma
-
Johnson & Johnson (JNJ) reports TALVEY and DARZALEX FASPRO based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
-
Johnson & Johnson (JNJ) Announces Red River Talc Files Voluntary Chapter 11
-
Johnson & Johnson (JNJ) Gets 83% Of Baby Powder Victims To Agree To New Talc Deal - Bloomberg
-
After summer drubbing, Edwards Lifesciences (EW) said targeted in takeover - source
-
Goldman Sachs Reiterates Buy Rating on CG Oncology (CGON)
-
Johnson & Johnson (JNJ) reports dexamethasone reduced infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT
-
Johnson & Johnson (JNJ) Announces Retirement of D. S. Davis from Board
-
Johnson & Johnson (JNJ) Reports RYBREVANT plus LAZCLUZE Showed strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
-
J&J (JNJ) Raises Settlement Offer by About $1 Billion to Roughly $9 Billion - WSJ
-
Johnson & Johnson (JNJ) seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
-
Johnson & Johnson's (JNJ) EVP, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
-
Johnson & Johnson (JNJ) To End Some Up-Front Discounts For Hospitals - WSJ
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ) after V-Wave deal
-
Johnson & Johnson (JNJ) to acquire V-Wave in deal worth up to $1.7bn
-
Johnson & Johnson gets green light for lung cancer combination treatment
-
Johnson & Johnson (JNJ) to Acquire V-Wave
-
Johnson & Johnson (JNJ) Announces RYBREVANT plus LAZCLUZE approved in the U.S.
-
Johnson & Johnson (JNJ) Preparing to Have Subsidiary Seek Bankruptcy Protection to Consummate Talc Settlement as Soon as Next Week - Reuters
-
Johnson & Johnson (JNJ) spreader active in August 155 and August 23 weekly 155 puts
-
J&J wins plaintiff support for $6.5 billion baby powder settlement - Bloomberg
